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ABSTRACT 
This study was designed to assess the relationship between psychopathology and serot-
onin generated prolactin response to clomipramine and to assess the relationship between im-
provement in psychopathology and prolactin levels. The experimental sample consisted of 15 
patients in the drug and 12 patients in the placebo groups. Blood samples for prolactin levels were 
drawn at baseline, and at the end of 4,8, and 12 weeks. There were statistically significant differ-
ences in prolactin increase between the drug and the placebo groups at 4 but not at 12 weeks 
following treatment. When the four least improved and a similar number of the most improved 
patients were compared, the least improved patients had the most increase in prolactin and the 
most improved had the least increase. 
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The unique symptomatology and 
manifestations of obsessive compulsive 
disorder (OCD) as well as recent technological 
advances have allowed researchers to gain 
insight into the pathophysiology of this 
disorder. Serotonin (5HT) dysregulation is 
implicated in OCD (Murphy et al., 1989). The 
implication of serotonin dysregulation in OCD 
is based on the indirect evidence that 
clomipramine, a potent serotonin uptake 
inhibitor, has been found to be useful in 
treating OCD (Ananth, 1985; Clomipramine 
Collaborative Study Group, 1991; Thoren etal., 
1980a; Zoharetal., 1987a; Grist etal., 1995a). 
Usefulness of other selective serotonin 
inhibitors (SSRI) such as fluvoxamine 
(Goodman et al., 1990; Mallaya et al., 1992; 
Freeman et al.. 1994; Greist 1995b), fluoxetine 
(Piggot et al., 1990; Montgomery et al., 1993; 
Tollefson et al., 1994), sertraline (Chouinard, 
1992; Jenike et al., 1990; Greist et al., 1995c) 
in the treatment of OCD provides further 
credence for serotonin involvement. 
Administration of pharmacological probes 
including trypt^ohan, a serotonin precursor 
(Charney et al 1988), fenfluramine a 5HT 
releaser (Hollander etal., 1988), metergolinea 
5HT antagonist (Piggot et al., 1991; Piggot et 
al., 1993) and meta-chlorophenylpiperazine 
(mCPP) (Barr et al., 1992; Zohar and Insel, 
1987; Zoharetal.,1987; Hollander etal.,1988; 
Charney etal., 1988; Piggot etal., 1991; Piggot 
et al., 1993; Goodman et al., 1995; Hollander 
et al., 1992) did not yield consistent and 
replicable response. 
There are multiple serotonin receptors 
(5-HTi to 5-HT7) cloned and subtyped (Lucki, 
1996; Hoyer et al.,1994; Kreiss and Lucki, 
1994). The list is never complete as the classi-
fication is ongoing with identification of new 
receptors. Genes are identified for the 5-HT1a, 
5-HTib, 5HT1d, 5HT1e, 5HTif, 5HT2a, SHTa, 
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5HT2c, 5HT3, 5HT5a, 5HT5b, 5HT6 and 5HT7  (Dubovsky & Thomas, 1995; Lovenberg et al., 
1993; Meltzer, 1990). To assign particular 
psychopathology to a particular receptor is not 
possible for a number of reasons: a) many of 
the drugs that are employed act on multiple 
receptors; b) interact and influence each other; 
c) it is unlikely that particular subtypes are 
involved in each psychiatric illness; d) OCD may 
be a heterogeneous group and thus different 
subtypes of 5HT receptors might be involved 
in different patients, and that OCD may be due 
to the generalized dysfunction of the 5HT 
system. 
There is evidence that 5HT regulates the 
secretion of prolactin (Coven etal.,1990; Lopez 
et al., 1987; Ben-Jonathan et al., 1989). An 
enhanced prolactin level after administration of 
clomipramine has been reported (Anderson & 
Coven, 1989; Hanna et al., 1991; Zohar et al., 
1988). A problem in interpreting these data 
includes the variance of physiologic, pathologic 
and pharmacologic factors that affect prolactin 
secretion. In addition, sensitivity of serotonergic 
system in OCD patients may differ from that in 
normal. Currently, the relationship between 
clomipramine administration and prolactin 
levels as well as psychopathology has not been 
definitively established. Therefore, this study 
was designed to assess the relationship between 
psychopathology and prolactin response to clo-
mipramine; and to ascertain the relationship 
between improvement in psychopathology and 
prolactin levels. 
MATERIAL AND METHOD 
Patients were diagnosed on the basis of 
a clinical interview and rating on the Yale Brown 
Obsessive Compulsive Rating Scale (YBOCS). 
Inclusion criteria was a diagnosis of OCD on 
the basis of SCID, of at least one year 
duration, a score of 20 or more on the YBOCS, 
and age range between 18 and 65 years, good 
physical health as well as normal electrocar-
diogram, biochemical tests, chest X-ray and eye 
tension. Exclusion criteria were the 
presence of physical illness, primary 
depression, epilepsy, history of head injury, 
thyroid disease, schizoid personality disorder 
based on SCID, drug and alcohol abuse, and/ 
or anyone on concomitant medication. The 
exclusion of schizoid personality is based on 
the finding of nonresponsiveness of these 
patients to clomipramine treatment (Baer and 
Jenike, 1989). 
The experimental sample consisted of 13 
males and 14 females with a mean age of 35.8 
years and a range between 19 and 64 years. 
The placebo group consisted of 4 males and 8 
females with a mean age of 36.6 years, and a 
range between 19 and 64 years. Similarly, the 
drug treated group consisted of 9 males and 6 
females with a mean age of 35 years and a 
range between 22 and 51 years. 
All selected patients were on placebo for 
one week,and during that week all investiga-
tions including a detailed physical examination, 
glaucoma test, chest X-ray, electrocardiogram 
and a battery of biochemical examination were 
conducted. According to a precoded design, 
only those with normal results were randomly 
assigned to either placebo or drug treatment. 
Half the patients were given placebo and the 
other half received gradually increasing doses 
of clomipramine up to 250 mg daily. Blood for 
prolactin levels were drawn at baseline, and at 
the end of'4,8 and 12 weeks on the same day 
as the clinical assessment. Each patient had 
four prolactin samples and there were no drop 
out in either group. On the day of the 
sample collection for prolactin estimation, 
patients were clinically interviewed on the ba-
sis of which the Yale Brown Obsessive 
Compulsive Scale was completed. There were 
no dropouts in either group. Blood was drawn 
between 8:00 and 8:30 A.M. in all patients, and 
in females blood was drawn a week after the 
menstrual cycle. Data was analysed using 
multiple correlation coefficient. Serum sample 
were analysed for prolactin by radio-immune 
assay with reagents obtained from the National 
Pituitary Agency (Poland & Robin, 1981). As 
determined by multiple high, medium, and low 
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serum pool replicates; maximum inter-and 
intra-assay variability was 13%. The lower limit 
of sensitivity using 50ng/ml. 
RESULTS 
a) Prolactin levels: In the clomipramine 
group, mean prolactin level of 7.79 ng/ml 
change to H.36ng/ml at the end of 4 weeks, to 
12.60 ng/ml at the end of eight weeks and to 
11.34 ng/ml at the termination. However, there 
was a significant change in prolactin levels 
across trials in this group (p<0.001). The change 
in prolactin level from 6.9 ng/ml at baseline to 
7.25 ng/ml at the end of 4 weeks, 7.35 ng/ml at 
the end of 8 weeks to 7.8 ng/ml at termination. 
There was no significant change in the prolac-
tin level for patients on placebo across trials. 
Between the placebo and the drug groups at 
the end of 4 and 8 weeks (t=2.81, df=25, p<00.9 
and t=2.995, df=25, p<.006, respectively) but 
not at the end of 12 weeks of the study, there 
were statistically significant difference in the 
mean prolactin level (Table). These prolactin 
levels did not correlate with gender for either 
group at any week of treatment except for the 
drug group at week 4 (t=2.27, p<.041) with 
females having significantly higher levels of 
prolactin. There was a statistically significant 
correlation between total YBOCS scores and 
the baseline prolactin level in the female 
population as a whole (r=.54 p<0.001). 
Dosage of medication insignificantly 
correlated with prolactin level at the end of 4 
weeks (r=.279) with a mean daily dose of 210 
mg, 8 weeks (r=-.353) with a mean daily dose 
of 230 mg, and 12 weeks (r=-.152) with a mean 
daily doseof 210 mg. 
b) Psychopathology: In the clomipramine 
group, the base-line YBOCS score of 28.1 
changes to 19 at the end of 4 weeks, 15.3 at 
the end of 8 weeks and 13.2 at the end of 12 
weeks and in the placebo group the baseline 
YBOCS scores of 27.9 changed to 26.9 at the 
end of 4 weeks, 25.2 at the end of 8 weeks and 
25.7 at the end of 12 weeks. There was a 
statistically significant 52.8% improvement in 
the drug group and 10% in the placebo group 
at termination. The improvement in the clomi-
pramine group at 4,8 and 12 weeks of treat-
ment (p<0.001) and the difference between the 
two groups (p<0.001) was statistically 
significant. Male patients improved better than 
the females (78% vs.51%) which was statisti-
cally significant (p<0.001). 
TABLE 
PROLACIN LEVELS IN PLACEBO AND CLOMIPRAMINE TREATED OCD PATIENTS 
Patients on 
placebo 
1M 
2M 
3M 
4M 
5F 
6F 
7F 
8F 
9F 
10F 
11F 
12F 
13 
14 
15 
WK 
0 
7.5 
3.9 
6.6 
8.1 
7.6 
8.9 
8.0 
7.8 
6.0 
5.0 
5.3 
8.1 
-
-
-
WK 
4 
11.4 
3.9 
6.6 
5.6 
6.5 
8.9 
4.4 
8.5 
13.0 
5.0 
5.3 
8.0 
-
-
-
WK 
8 
8.7 
6.1 
7.0 
8.5 
7.6 
8.5 
6.7 
7.3 
7.6 
6.5 
7.4 
6.3 
-
-
-
WK 
12 
11.4 
5.6 
7.5 
7.2 
7.6 
7.3 
8.1. 
8.2 
7.6 
6.5 
10.9 
6.5 
-
-
-
Patients on 
clomi-
pramine 
1M 
m 
m 
4M 
5M 
6M 
7M 
8M 
9M 
10F 
11F 
12F 
13F 
14F 
15F 
WK 
0 
4.9 
8.6 
8.6 
9.6 
7.2 
4.8 
8.3 
6.5 
5.7 
5.7 
9.3 
9.6 
4.0 
15.5 
8.6 
WK 
4 
13.1 
13.0 
8.4 
10.4 
12.9 
9.9 
13.2 
8.4 
8.4 
14.0 
15.5 
12.5 
7.4 
35.5 
32.5 
WK 
8 
12.3 
5.9 
9.9 
11.0 
13.4 
9.4 
13.2 
8.3 
9.2 
12.7 
10.8 
13.4 
8.2 
21.1 
30.3 
WK 
12 
11.0 
7.6 
9.1 
11.0 
13.9 
4.1 
13.1 
9.2 
2.5 
6:1 
9.5 
13.4 
7.0 
13.7 
39.0 
1S6 OCD : CLOMIPRAMINE, PROLACTIN AND THERAPEUTIC RESPONSE 
c) Psychopathology and prolactin level 
interactions: There was a significant negative 
correlation between YBOCS scores and serum 
prolactin levels (r= - 0.50, p<0.05) for the en-
tire group at the end of four weeks and no other 
significant correlation was noted. There was 
essentially no correlation between psychopa-
thology and prolactin level for those on drug at 
baseline (r=-0.18) and throughout week 8 (r= -
0.05 r= - 0.08), and only a modest correlation 
at 12 week (r= 0.36). 
d) The best and the worst responders: 
The four most improved patients were com-
pared with the four least improved ones. The 
total YOBCS score of the four with least im-
provement changed from 104 to 99 and that of 
most improved changed from 116 to 23 
(p<0.001). The total prolactin level of the least 
improved group changed from an initial level 
of 33 to a final level of 72 with an average daily 
dose of 250 mg of clomipramine (Table). On 
the other hand, the prolactin level of the most 
improved group did not change throughout the 
study. The differences in prolactin increase 
between the two groups was significant 
(p<0.001). In fact, the resistant group had a 
higher increase in prolactin levels. 
DISCUSSION 
In the total population of 27 patients, 
initial prolactin levels correlated significantly 
(r= - 0.4, p>0.01) with the total YOBCS scores 
in females and not in males. There were 
statistically significant differences in prolactin 
increase between the drug (15 patients) and the 
placebo (12 patients) groups at 4 but not at 12 
weeks following treatment. These levels were 
not significantly related td drug dosage, psy-
chopathology, age or gender. When the four 
least improved and a similar number of the most 
improved patients were compared, the least 
improved patients had the most increase in 
prolactin and the most improved had the least 
increase. 
These findings lend themselves to a 
number of interpretations: 1) optimal prolactin 
response occurs at four weeks and no later, and 
a correlation of YBOCS scores and prolactin 
increase exists at four weeks only; 2) serotonin 
increase as reflected by increase in prolactin 
may not be the mechanism of action of 
clomipramine in OCD; and 3) prolactin may not 
be an adequate marker for serotonin function; 
4) the findings may be a chance factor due to 
the small sample size. 
However, the finding that the most 
improved had the least increase in prolactin, 
provides evidence for the down regulation of 
the postsynaptic serotonin receptors. Delay in 
onset of action on obsessive compulsive 
symptoms noted in many of the studies 
supports this down regulation indirectly. To 
prove these intricate relationships, it is 
important to carry out a study with a large 
number of patients and normal controls. 
REFERENCES 
Ananth, J. (1985) Pharmacotherapy of 
obsessive compulsive disorder. In. Obsessive 
Compulsive Disorder, (Eds) Mavissakalian, M., 
Turner, S.M. and Michelson, L., pp 167-239, New 
York Plenum Press, 
Anderson, I.M. & Coven P.J. (1989) 
Clomipramine enhances prolactin, and growth 
hormone responses to tryptophan. Psychopharma-
cology, 89, 131-133. 
Barr, L.C., Goodman, W.K., Price, L.H., 
McPougle, C.J. & Charney, D.S. (1992) The 
serotonin hypothesis of Obsessive compulsive dis-
order. Implications of challenge studies. Journal of 
Clinical Psychiatry, 53 (Suppl 4), 17-28. 
Baer, L. & Jenike M.A. (1989) Personality 
disorders in obsessive compulsive disorders In: 
Obsessive Compulsive Disorders Theory and man-
agement, II Edition,! Eds.) L, Baer and M A. Jenike, 
pp76-88, Chicago: Yefar.Book Publishers. 
Ben-Jonathan, N., Arbogast, L.A. & Hyde. 
J.F. (1989) Neuroendocrine regulation of prolactin 
release Progress in Neurobiology, 33, 399-447. 
Charney, D.S., Goodman, W.K., Price, L.H., 
Woods, S.W., Rasmussen, S.A. & Heninger, G.R. 
157 JAMBUR ANANTH et al. 
(1988) Serotonin function in obsessive compulsive 
disorder. Archives of General Psychiatry, 45, 177-
185. 
Charney, D.S., Goodman, W,K., Price L.H., 
Wood, S.W., Rasmussen, S.A. & Heninger, G.R. 
(1988) Serotonin function in obsessive-compulsive 
disorder: a comparison of the effects of tryptophan 
and m-chlorophenylpiperazine in patients and 
healthy subjects. Archives of General Psychiatry, 
45, 177-185. 
Chouinard, G. (1992) Sertraline in the treat-
ment of obsessive compulsive disorder. Two dou-
ble blind placebo controlled studies. International 
Clinical Psychopharmacology, 7 (Suppl 2), 37 41. 
Clomipramine Collaborative Study Group 
(1991) Clomipramine in the treatment of patients 
with obsessive compulsive disorder. Archives of 
General Psychiatry, 48, 730-738. 
Coven, P. J., Anderson, I.M. & Garside, S.E, 
(1990) Endocrinological responses to 5-HT. Annals 
of New York Academy of Medical Science, 600, 250-
257. 
Dubovsky, S.L. & Thomas, M. (1995) 
Serotonergic mechanisms and current and future 
psychiatric practice. Journal of Clinical Psychiatry, 
56 (Suppl 2), 38-46. 
Freeman, C.P., Trimble, M.R., Deakin, J.F., 
Stokes, T.M. & Ashford, J.J. (1994) Fluvoxamine 
versus clomipramine in the treatment in obsessive 
compulsive disorder: a multicenter randomized dou-
ble blind, parallel-group comparison. Journal of Clini-
cal Psychiatry, 55, 301-305. 
Goodman, W.K., Price, L.H., Delgado, P.L., 
Palumbo, J., Krystal, J.H., Nagy, L.M., 
Rasmussen, S.A., Heninger, G.R. & Charney, D.S. 
(1990) Specificity of serotonin reuptake inhibitors 
in the treatment of obsessive compulsive disorder. 
Comparison of fluvoxamine and desipramine. Ar-
chives of General Psychiatry, 48, 483-484. 
Goodman, W.K., Mcdougle, C.J., Price, 
L.H., Barr, L.C., Hills, O.F., Caplik, J.F., Charney 
D.S. & Heninger, G.R. (1995) m-chlorophenyl-
piperazine in patients with obsessive compulsive 
disorder Absence of symptoms exacerbation. 
Biological Psychiatry, 38, 138-149 
Greist, J.H., Jefferson, J.W., Kobak, K.A., 
Katzelnick, D.J. & Serlin, R.C. (1995a) Efficacy 
and tolerability of serotonin transport inhibitors in 
obsessive-compulsive disorder. Archives of General 
Psychiatry, 52, 53-60. 
Greist, J.H., Jenike, M.A., Robinson, D. & 
Rasmussen, S.A. (1995b) Efficacy of fluvoxamine 
in obsessive compulsive disorder, results of 
multicenter, double blind, placebo controlled trial. 
European Journal of Clinical Research, 7, 195-204. 
Greist, J.H., Jefferson, J.W., Kobak, K.A. 
& Chouinard, G. (1995c) A one year double blind 
placebo controlled fixed dose study of sertraline in 
the treatment of obsessive compulsive disorder. 
International Clinical Psychopharmacology, 
10, 57-65. 
Hanna, G.L, McCraken, J.J. & Cantwell, 
D.P. (1991) Prolactin in childhood obsessive com-
pulsive disorder. Clinical correlates and response 
of clomipramine. Journal of American Academy of 
Child and Adolescent Psychiatry, 30, 173-178. 
Hollander, E., Fay, M., Cohen, B., 
Campeas, R., Gorman, J.M. & Liebowitz, M.R. 
(1988) Serotonergic and noradrenergic sensitivity 
compulsive disorder- behavioural findings. Ameri-
can Journal of Psychiatry, 145, 1015-1018. 
Hollander, E., Decrial, CM., Nitescu, A., 
Gully, R., Suckow, R.F., Cooper, T.B., Gorman 
J.M., Klein, D.F. & Leebowitz. M.R. (1992) 
Serotonergic function in obsessive compulsive dis-
order: behavioral and neuroendocrine responses 
to oral m-chlorophenylpiperazine and fenfluramine 
in patients and healthy volunteers. Archives of Gen-
eral Psychiatry, 49, 21-28. 
Hoyer, D., Clarke, D.E., Fozard, J.R., 
Hartig., P.R. Martin, G.R., Mylecharane, E.J., 
Saxena P.R. & Humphrey, P.P. (1994) VII: Interna-
tional union pharmacology classification of recep-
tors for 5 hydroxytrptamine (serotonin). Pharmaco-
logical Review, 46, 157-203. 
Insel, T.R., Meuller, E.A., Alterman, I., 
Linnoila, M. & Murphy, D.L. (1985) Obsessive 
compulsive disorder and serotonin: Is there a 
connection? Biological-Psychiatry, 20, 1174-1188. 
Jenike, M.A., Baer, L., Summergrad, P., 
Minichiello, W.E., Holland, A. & Seymor, R. (1990) 
Sertraline in obsessive compulsive disorder: a dou-
ble blind comparison with placebo. American Jour-
nal of Psychiatry, 147, 923-928. 
158 OCD : CLOMIPRAMINE, PROLACTIN AND THERAPEUTIC RESPONSE 
Kreiss, D.S. & Lucki, I. (1990) Differential 
regulation of serotonin (5HT) release in the stratum 
and hippocampus by 5HT1a autoreceptors of the 
dorsal and median raphe nuclei. Journal of Phar-
macology & Experimental Therapy. 169,1268-1279. 
Lopez, R, Gonzalez, D. & Aguilar, E. (1987) 
Possible direct effect of serotonin on 
pituitary prolactin secretion in vivo and in vitro stud-
ies. Hormone Research, 25, 160-170. 
Lovenberg, T.W., Erlander, M.G., Baron, 
B.M., Racke, M., Stone, A.L, Siegel, B.W., Craft 
CM., Burns, J.E., Danielson, P.E. & Sutcliffe, J.G. 
(1993) Molecular clonig and functional expression 
of 5HT1E like rat and human 5-hydroxytryptamine 
receptor genes. Proceeding's of National Academy 
of Sciences, USA, 90, 2184-2188. 
Lucki, I. (1990) Serotonin receptor specifivity 
in anxiety disorder. Journal of Clinical Psychiatry, 
57 (suppl), 5-10. 
Mallaya, G.K., White, K., Waternaux, C. & 
Quay, S. (1992) Short-and long term treatment of 
obsessive compulsive disorder. Annals of Clinical 
Psychiatry, 4, 77-80. 
Meltzer, H.Y. (1990) Presynaptic receptors: 
relevance to psychotropic drug action in man. 
Annals of New York Academy of Medical Science, 
604, 353-365. 
Montogmery, S.A., Mcntyre, A., 
Osterheider, M., Sarteschi, P., Zitterl, W., Zohar, 
J., Birkett, M. & Wood, A.J. (1993) A double blind 
placebo controlled study of fluxetine in patients with 
DSM IIIR obsessive compulsive disorder. European 
Neuropsychopharmacology, 3, 143-152. 
Murphy, D.L., Zohar, J., Benkelfat, C, 
Pato, M.T., Pigott, T.A. & Insel, T.R. (1989) Ob-
sessive compulsive disorder as a 5-HT subsystem-
related behavioural disoder. British Journal of Psy-
chiatry, 155, 15-24. 
Pigott, T.A., Hill, J.L, Grady, T.A., Heureux, 
u., Berstein, S., Rubenstein, C.S. & Murphy, D.L. 
(1993) A comparison of the behavioral effects of 
oral vs intravenous mcpp administration in OCD 
patients and the effects of metergoline prior to IV 
mcpp. Biological Psychiatry, 33, 3-14. 
Pigott, T.A., Zohar, J., Hill, J.A., Berstein, 
S., Groven, G.N., Zohar-Kadouch, R.C. & Murphy, 
D.L. (1991) Metergoline blocks the behavioural 
effects pf oral versus intravenous m-chlorophen-
ylpiperazine in patients with obsessive compulsive 
disorder. Biological Psychiatry, 29, 418-426. 
Piggot, T.A., Pato, M.T., Bernstein, S.E., 
Gorver, G.N., Hill, J.L., Tolliver, T.J. & Murphy, 
D.L. (1990) Controlled comparison of clomipramine 
and fluxetine in the treatment of obsessive compul-
sive disorder. Behavioral and biological results. 
Archives of General Psychiatry, 47, 926-932. 
Poland, R.E. & Pubin, R.T. (1981) 
Radioimmune assay of haloperidol in human 
serum: Correlation of serum haloperidol with serum 
prolactin. Life Sciences, 29, 1837-1845. 
Thoren, P., Asberg, M., Cronholm, B., 
Jornestedt, L. & Traskman, L. (1980a) 
Clomipramine treatment of obsessive-compulsive 
disorder. Archieves of General Psychiatry, 37,1281-
1285. 
Thoren, P., Asberg, M., Mellstrom, B., 
Sjoqvist, F. & Traskman, L. (1980b) 
Clomipramine treatment of obsessive-compulsive 
disorder. II. Biochemical aspects. Archieves of 
General Psychiatry, 37, 1281-1285. 
Tollefson, G.D., Rampey, A.H., Potvin, 
J.H., Jenike, M.A., Rush, A.J., Dominguez, R.A., 
Koran, L.M., Shear, K., Goodman, W. & Genduso 
L.A. (1990) A multicenter investigation of fixed 
dose fluoxetine in the treatment of obsessive com-
pulsive disorder. Archieves of General Psychiatry, 
51, 559-567. 
Zohar, J. & Insel, T.R. (1987) Psychobi-
ological approaches to diagnosis, treatment and 
pathophysiology . Biological Psychiatry, 22,667-687 
Zohar, J., Mueller, E.A., Insel, T.R., Zohar-
Kadouch, R.C., Murphy, R.C & Murphy, D.L. 
(1987) Serotonergic responsivity in obsessive-com-
pulsive disorder. Archieves of General Psychiatry, 
44, 946-951. 
Zohar, J., Insel, T.R., Zohar-Kadouch, R.C, 
Hill, J.L. & Murphy,. D. (1938) Serotoninergic 
responsivity in obsessive compulsive disorder: Ef-
fects of chronic administration of clomipramine treat-
ment Archieves of General Psychiatry, 45, 167-
172. 
JAMBUR ANANTH. M.D.,' AMRIT KAUR, M.D.. RUSSELL POLAND. Ph.D. & MARCHY WOHL, R.N.. all from Harbor-
UCLA Medical Center. 1000 W, Carson Street. Building 1-South Torrance, CA 90509, USA. 
'Correspondence 
159 